CRSP Stock Is On A Wild Ride After Sickle Cell Treatment Approval. These Diseases Could Be Next.
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology.
Audio is streamed directly from the publisher (pdst.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease.
Government approval of these groundbreaking treatments could generate an unprecedented wave of medical innovation. But gene editing therapies aren't without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.
On this episode of Growth Stories, we dive into the science of gene editing treatments and how the boom in gene therapy drug approvals could transform the healthcare industry.
Learn more about your ad choices. Visit megaphone.fm/adchoices